Nostrum Labs Agrees to Pay Up to $50 Million Over Underpayment of Medicaid Rebates

Nostrum Laboratories and its CEO have struck a potential $50 million settlement with the Department of Justice (DOJ) to resolve allegations the company knowingly underpaid Medicaid rebates for its Nitrofurantoin…

Continue ReadingNostrum Labs Agrees to Pay Up to $50 Million Over Underpayment of Medicaid Rebates

FDA AdComm Will Review Vertex’s Off-Target Effects Data for Sickle Cell Gene Therapy

Whether Vertex Pharmaceuticals’ off-target safety analysis of its investigational sickle cell gene therapy exagamglogene autotemcel (exa-cel) is sufficient or not is the issue before an FDA advisory committee on Tuesday…

Continue ReadingFDA AdComm Will Review Vertex’s Off-Target Effects Data for Sickle Cell Gene Therapy